Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …

Advances in RNA-sequencing techniques have led to the discovery of thousands of non-
coding transcripts with unknown function. There are several types of non-coding linear …

The competitive endogenous RNA (ceRNA) hypothesis proposes that transcripts with
shared microRNA (miRNA) binding sites compete for post-transcriptional control. This …

Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of
several human cancers, including breast cancer (BC), as strong evidence has been found …

MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial
roles in regulating gene expression. Increasing evidence supports a role for miRNAs in …

Early studies have shown how aberrantly expressed microRNAs are a hallmark of several
diseases like cancer. MicroRNA expression profiling was shown to be associated with …

Many RNA species have been identified as important players in the development of chronic
diseases, including cancer. Over the past decade, numerous studies have highlighted how …

MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression
post-transcriptionally. As a consequence of their function towards mRNA, miRNAs are …

Cancer is one of the leading cause of death in the world with the prevalence of> 10 million
mortalities annually. Current cancer treatments include surgical intervention, radiation, and …